Prostate cancer treatment with the only AI-powered, MRI-guided, incision-free robotic ablation. TULSA-PRO delivers proven prostate cancer control without compromising quality of life. By transforming treatment with an MRI-centered pathway, we ensure precision, and flexibility, while delivering a better patient experience.
LEARN MORE

AUA 2025

Las Vegas, Nevada
April 26 – 29

Join us live at AUA to learn more about TULSA-PRO. Visit us at booth #654, attend our educational events, or contact us for more information.

Book your exclusive preview of our TULSA-AI Volume Reduction module, designed to ablate prostate tissue in men with BPH and LUTS in 60-90 minutes.

Calendar Calendar Book Your Demo

AUA Speaker Schedule

Saturday April 26
9:30AM-11:30AM

MP04-02: MRI-Guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: Single Institution Experience of Treatment Efficacy​

Speaker: Dr. Jonathan Balcazar, UT Southwestern Medical Center​
Type: Moderate Poster Session
Room: Casanova 503​

MP06-19: Deep learning prostate segmentation module to assist in MRI-guided transurethral ultrasound (TULSA) treatment planning: validation study and real-world performance​

Speaker: Dr. Mark Hong​
Type: Moderate Poster Session
Room: Marco Polo 703​

Sunday April 27
3:30PM-5:30PM

PD19-01: Final, three-year oncological results of a randomized clinical trial FARP comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer

Speaker: Dr. Eduard Baco, Oslo University Hospital
Type: Podium
Time: 3:30PM-3:38PM
Room: Marco Polo 805 ​​

PD19-07: Real-world outcomes after MRI-guided transurethral ultrasound ablation of the prostate in a multicenter post-market registry​

Speaker: Dr. Ram Pathak, Mayo Clinic Florida, on behalf of the CARE registry
Type: Podium
Time: 4:18PM-4:26PM
Room: Marco Polo 805 ​​

Monday April 28
1:00PM-3:00PM

Successfully recruited: CAPTAIN randomized controlled trial comparing the TULSA procedure against radical prostatectomy

Speaker: Dr. Xiaosong Meng, UT Southwestern Medical Center, on behalf of the CAPTAIN trial
Type: Late-Break Session
Time: 2:04PM-2:12PM
Room: Hall C, The Square, Learning Lab​

CAUTION: TULSA-PRO® is approved for commercial sale in the USA (K191200) & EU (CE 2797). Rx only device.

For all other Regulatory jurisdictions, please contact us at info@profoundmedical.com for more information regarding the regulatory status of the device.